Low-Dose Ibutilide Combined with Catheter Ablation of Persistent Atrial Fibrillation: Procedural Impact and Clinical Outcome
المؤلفون المشاركون
Shah, Ashok J.
Yang, Xinchun
Sun, Xue-Rong
Tian, Ying
Yin, Xian-Dong
Shi, Liang
Wang, Yan-Jiang
Liu, Xiao-Qing
Liu, Xing-Peng
Hocini, Meleze
Haissaguerre, Michel
المصدر
Cardiology Research and Practice
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-10، 10ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-01-02
دولة النشر
مصر
عدد الصفحات
10
التخصصات الرئيسية
الملخص EN
Background.
In patients with persistent atrial fibrillation (AF), the procedural and clinical outcomes of ablation combined with infusion of antiarrhythmic drug are unknown.
Objectives.
To determine the impact of low-dose ibutilide after circumferential pulmonary vein isolation (CPVI) and/or left atrial (LA) substrate modification on acute procedural and clinical outcome of persistent AF.
Methods.
In a prospective cohort of 135 consecutive patients with persistent AF, intravenous 0.25 mg ibutilide was administered 3 days before the procedure and intraprocedurally, if required, after CPVI and/or additional LA substrate modification of sites with continuous, rapid or fractionated, and low-voltage (0.05–0.3 mv) atrial activity.
Results.
Persistent AF was terminated by CPVI alone (n=15) or CPVI + ibutilide (n=32) in 47 (34.8%) patients (CPVI responders).
Additional LA substrate modification without (n=33) or with subsequent administration of 0.25 mg ibutilide (n=19) terminated AF in another 52 (38.5%) patients (substrate modification responders).
Sinus rhythm was restored by electrical cardioversion in the remaining 36 (26.7%) patients (nonresponders).
The mean LA substrate ablation time was 14 ± 6 minutes.
At follow-up of 24 ± 10 months, the rates of freedom from atrial tachyarrhythmias among the responders in CPVI and substrate modification groups were mutually comparable (66.0% and 69.2%) and higher than among the nonresponders (36.1%; P<0.01).
Among the responders, there was no difference in clinical outcome between patients whose persistent AF was terminated without or with low-dose ibutilide.
Conclusion.
Administration of low-dose ibutilide during ablation of persistent AF may allow select patients wherein substrate ablation is not or minimally required to optimize procedural and clinical outcomes.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Sun, Xue-Rong& Tian, Ying& Shah, Ashok J.& Yin, Xian-Dong& Shi, Liang& Wang, Yan-Jiang…[et al.]. 2019. Low-Dose Ibutilide Combined with Catheter Ablation of Persistent Atrial Fibrillation: Procedural Impact and Clinical Outcome. Cardiology Research and Practice،Vol. 2019, no. 2019, pp.1-10.
https://search.emarefa.net/detail/BIM-1145915
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Sun, Xue-Rong…[et al.]. Low-Dose Ibutilide Combined with Catheter Ablation of Persistent Atrial Fibrillation: Procedural Impact and Clinical Outcome. Cardiology Research and Practice No. 2019 (2019), pp.1-10.
https://search.emarefa.net/detail/BIM-1145915
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Sun, Xue-Rong& Tian, Ying& Shah, Ashok J.& Yin, Xian-Dong& Shi, Liang& Wang, Yan-Jiang…[et al.]. Low-Dose Ibutilide Combined with Catheter Ablation of Persistent Atrial Fibrillation: Procedural Impact and Clinical Outcome. Cardiology Research and Practice. 2019. Vol. 2019, no. 2019, pp.1-10.
https://search.emarefa.net/detail/BIM-1145915
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1145915
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر